QualityStocks'  Instablog

Yesterday, Elephant Talk Communications Corp. announced the completion of a registered direct public offering of an aggregate $12.0 million, which was led by a $4.5 million investment from company CEO Steven van der Velden, a $5.0 million investment from Crede CG III Ltd. (a wholly owned subsidiary of Crede Capital Group LLC) and investors placed by Dawson James Securities to purchase an additional $2.5 million. The company sold an aggregate of 17,425,638 shares of common stock, par value $0.00001 per share, and warrants for purchasing up to an aggregate of 7,841,537 shares of common stock.

The shares are being sold to non-affiliate investors at $0.682 per share and to the affiliated investor (van der Velden) at $0.70 per share. The warrants have an initial exercise price of $0.887 per warrant share for both the affiliated investor and the non-affiliated investors. NYSE MKT notified Elephant Talk Communications on June 13 of its acceptance of the company's plan of compliance; this was one of the closing conditions of the offering.

The gross proceeds realized by Elephant Talk Communications in connection with the offering are $12.0 million, and the net proceeds are anticipated to be around $11.4 million after deducting the placement agent and estimated offering expenses. A portion of the net proceeds from the offering will be used by Elephant Talk Communications to pay all outstanding obligations of around $6.7 million, pursuant to certain purchase agreements with the holders of certain senior secured convertible notes that the company issued on March 29, 2012. The remaining net proceeds will be used for working capital and other general corporate purposes.

Following this successful closing of the registered public offering, Elephant Talk Communications' management plans to focus on growing the company's topline while diligently moving Elephant Talk Communications toward being consistently operational cash flow-positive.

"I believe that the recent fund raisings were an integral component of the NYSE MKT's decision to accept the company's plan to regain compliance," CEO and Chairman van der Velden said. "Using the proceeds to repay existing debt strengthens the company's financial position by providing liquidity and significantly lowering the company's outstanding debt. In addition, the company's recent milestones of nearly reaching a positive cash flow position in March and receiving an additional $1.5 million of funding in May provide very positive momentum moving forward."

For more information, visit elephanttalk.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

It's not something you'd expect to find in a regenerative medicine company's portfolio, but Cardium Therapeutics' To Go Brands healthy nutraceutical supplement business is complementary to the company's overarching mission of meeting unmet medical needs as part of an individual's overall health and wellness.

Cardium in October 2012 acquired the assets, business, and product portfolio of To Go Brands, which develops and markets more than 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles.

The brand's Healthy To Go product line offers a host of healthy product offerings distributed through mass food and drug channels at retailers such as Whole Foods, CVS, Kroger, GNC, Vitamin Shoppe, and more.

Within Cardium's medical opportunities portfolio is its lead commercial product, Excellagen®, topical gel for wound care management. Excellagen is FDA-approved for the marketing and sale in the United States. In addition to its plans to advance Excellagen's commercial reach in the U.S. and internationally, Cardium plans to develop new extensions for additional wound care applications, and its working to achieve regulatory approval for the marketing and sale of the product in South Korea and the European Union.

The company's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its phase 3 registration study for Generx in Russia.

For more information, visit cardiumthx.com or togobrands.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

The equity markets are constantly moving and it is imperative that an active trader can find out what is happening in real-time. Even if you aren't trading all day long - it is important to stay on top of the latest-breaking news. That is why we created our Twitter account just for you.

By following us at Twitter, you will be right on top of the action in the micro-cap and small-cap markets. You will receive short alerts regarding stock movements, news releases, and our new "Ones to Watch." Every week we send dozens of tweets to bring our followers the hottest stocks and headlines.

The news about the quality of our Twitter service has spread rapidly. As of today, we have more than 115,000 followers.

If you like to start following us, please visit our page at: www.twitter.com/QualityStocks

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net